TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
Study Details
Study Description
Brief Summary
Primary objective: To compare the pharmacokinetics of rifapentine and 25-desacetyl rifapentine at three different doses: 600 mg, 900 mg, and 1200 mg.
Secondary objective: To describe any correlation between pharmacokinetic parameters of three different doses of rifapentine plus a standard dose of isoniazid and the occurrence of toxicity attributed to anti-tuberculosis treatment.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
We will enroll 24-36 patients, 8-12 at each dose of 600, 900 and 1200 mg rifapentine Admissions for pharmacokinetic studies will take place during the continuation phase of tuberculosis therapy. Patients participating in a double-blinded trial of the tolerability and safety of higher doses of rifapentine during continuation phase therapy and consenting to participate in the pharmacokinetic study may be admitted to a Clinical Research Center (CRC) to allow for frequent blood sampling over a 24-hour period. Otherwise, patients will be evaluated in the clinic.
Study Design
Outcome Measures
Primary Outcome Measures
- Compare the pharmacokinetics of rifapentine and 25-desacetyl rifapentine at three difference doses: 600 mg, 900 mg, and 1200 mg []
Secondary Outcome Measures
- Describe any correlation between pharmacokinetic parameters of three different doses of rifapentine plus a standard dose of isoniazid and the occurrence of toxicity attributed to anti-tuberculosis treatment. []
Eligibility Criteria
Criteria
Inclusion:
Patients enrolled in TBTC Study 25 Informed consent
Exclusion:
Severe anemia (Hct <25%) Any severe adverse event related to study drugs in TBTC Study 25
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Central Arkansas Veterans Health System | Little Rock | Arkansas | United States | 72205 |
2 | LA County/USC Medical Center | Los Angeles | California | United States | 90033 |
3 | University of California, San Francisco | San Francisco | California | United States | 94110 |
4 | Denver Department of Public Health and Hospitals | Denver | Colorado | United States | 80204 |
5 | Washington, D.C. VAMC | Washington | District of Columbia | United States | 20422 |
6 | Chicago VA Medical Center (Lakeside) | Chicago | Illinois | United States | 60611 |
7 | Hines VA Medical Center | Hines | Illinois | United States | 60141 |
8 | Johns Hopkins University School of Medicine | Baltimore | Maryland | United States | 21287-0003 |
9 | Boston Medical Center | Boston | Massachusetts | United States | 02118 |
10 | New Jersey Medical School | Newark | New Jersey | United States | 07107-3001 |
11 | New York University School of Medicine | New York | New York | United States | 10016 |
12 | Columbia University/Presbyterian Medical Center | New York | New York | United States | 10032 |
13 | Harlem Hospital Center | New York | New York | United States | 10037 |
14 | Carolinas Medical Center | Charlotte | North Carolina | United States | 28203 |
15 | Duke University Medical Center | Durham | North Carolina | United States | 34222 |
16 | Nashville VA Medical Center | Nashville | Tennessee | United States | 37212-2637 |
17 | University of North Texas Health Science Center | Fort Worth | Texas | United States | 76107-2699 |
18 | Thomas Street Clinic | Houston | Texas | United States | 77009 |
19 | Audi L. Murphy VA Hospital | San Antonio | Texas | United States | 78284 |
20 | Seattle King County Health Department | Seattle | Washington | United States | 98104 |
21 | University of British Columbia | Vancouver | British Columbia | Canada | Canada V5Z 4R4 |
22 | University of Manitoba | Winnipeg | Manitoba | Canada | CANADA R3A 1R8 |
23 | Montreal Chest Institute McGill University | Montreal | Quebec | Canada | H2X 2P4Pq Canada |
Sponsors and Collaborators
- Centers for Disease Control and Prevention
- US Department of Veterans Affairs
Investigators
- Principal Investigator: Marc Weiner, MD, Audie L. Murphy VA Medical Center, San Antonio TX
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- CDC-NCHSTP-2558
- TBTC Study 25PK